Mizuho analyst Vikram Malhotra upgraded Healthpeak to Buy from Neutral with a price target of $25, down from $29. While risks exist, the overall risk/reward for Healthpeak is positive, the analyst tells investors in a research note. The stock has de-rated materially during the last 12 months on growing concerns around its life science tenant base, says the firm. However, its "deep-dive" suggests the company’s tenant base is strong from a cash runway perspective, and risks of credit issues are small and manageable.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PEAK:
- PEAK Earnings this Week: How Will it Perform?
- Healthpeak initiated with an Equal Weight at Wells Fargo
- Citi downgrades Healthpeak, likes Alexandria for life science exposure
- Healthpeak downgraded to Neutral from Buy at Citi
- Healthpeak downgraded at Scotiabank on Life Science segment’s tougher outlook
